» Articles » PMID: 28918172

Melatonin and Periodontal Tissues: Molecular and Clinical Perspectives

Overview
Journal Pharmacol Res
Publisher Elsevier
Specialty Pharmacology
Date 2017 Sep 18
PMID 28918172
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Periodontal disease is a frequent chronic inflammatory pathology that implies the destruction of the tissues supporting the teeth, which represents a high sanitary cost. It usually appears associated with other systemic conditions such as diabetes, metabolic syndrome, depression and Alzheimer disease among others. The presence of melatonin and its receptors in the oral cavity supports the hypothesis that this hormone could play a role in homeostasis of periodontal tissues. In the present review we will discuss the potential role of melatonin, a circadian synchronizing hormone, with proved antiinflammatory and antioxidant profile, in the pathogenesis and treatment of periodontitis. Particular emphasis will be placed on the role of the indolamine in the treatment of periodontal disease when this oral condition is comorbid with other pathologies that would also benefit from the therapeutic potential of melatonin and its analogs through diverse mechanisms.

Citing Articles

Periodontal disease in down syndrome: Predisposing factors and potential non-surgical therapeutic approaches.

Ghaffarpour M, Karami-Zarandi M, Rahdar H, Feyisa S, Taki E J Clin Lab Anal. 2024; 38(1-2):e25002.

PMID: 38254289 PMC: 10829694. DOI: 10.1002/jcla.25002.


Circadian clock-A promising scientific target in oral science.

Feng G, Zhao J, Peng J, Luo B, Zhang J, Chen L Front Physiol. 2022; 13:1031519.

PMID: 36467684 PMC: 9708896. DOI: 10.3389/fphys.2022.1031519.


Osteoporosis and Alveolar Bone Health in Periodontitis Niche: A Predisposing Factors-Centered Review.

Zhu L, Zhou C, Chen S, Huang D, Jiang Y, Lan Y Cells. 2022; 11(21).

PMID: 36359775 PMC: 9657655. DOI: 10.3390/cells11213380.


Hormone and implant osseointegration: Elaboration of the relationship among function, preclinical, and clinical practice.

Yi M, Yin Y, Sun J, Wang Z, Tang Q, Yang C Front Mol Biosci. 2022; 9:965753.

PMID: 36188222 PMC: 9522461. DOI: 10.3389/fmolb.2022.965753.


Response to Treatment with Melatonin and Clonazepam versus Placebo in Patients with Burning Mouth Syndrome.

Castillo-Felipe C, Tvarijonaviciute A, Lopez-Arjona M, Pardo-Marin L, Pons-Fuster E, Lopez-Jornet P J Clin Med. 2022; 11(9).

PMID: 35566642 PMC: 9101769. DOI: 10.3390/jcm11092516.